search

Active clinical trials for "Precursor Cell Lymphoblastic Leukemia-Lymphoma"

Results 1611-1620 of 1817

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

Hematologic MalignanciesAcute Myeloid Leukemia4 more

This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic hematopoietic cell transplantation (HCT) in adult subjects aged 18 years and older with hematologic malignancies. A total of 88 study subjects were treated in the trial at approximately 15 centers in the US.

Completed27 enrollment criteria

Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia...

LeukemiaMyeloid4 more

The investigators focused on patients with refractory acute leukemia or MDS and designed a phase 1 trial of escalated cladribine doses in the Cla-Flu-Bu RTC regimen using PK-guided myeloablative busulfan doses. This scheme allows combining different optimization of RTC experienced over years (Flu-Bu RTC, PK-guided myeloablative busulfan doses, a second purine analog cladribine) to approach a specific platform to treat refractory diseases.

Unknown status18 enrollment criteria

A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL

Acute Lymphoblastic Leukemia

A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL

Unknown status8 enrollment criteria

Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy...

Acute Lymphoblastic Leukemia

The present study was conducted to assess the population pharmacokinetics of 6-mercaptopurine (6-MP) in Pediatric Acute Lymphoblastic Leukemia (ALL) and genetic polymorphisms

Unknown status4 enrollment criteria

Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers

Hodgkin's LymphomaNon-Hodgkin's Lymphoma7 more

This trial investigates stem cell transplants from partially mismatched donors in patients with blood and bone marrow cancers. The trial will test two kinds of transplants - a full intensity transplant using a high dose of radiotherapy and chemotherapy, and a reduced intensity transplant with lower doses of chemotherapy and radiotherapy. Patients will be entered for the treatment pathway that is most appropriate for their level of health and fitness

Unknown status33 enrollment criteria

GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL....

Acute Lymphoblastic Leukemia

The present study aims at verifying the state of the art in what this illness concerns and at organizing a centralized samples analysis.

Unknown status4 enrollment criteria

CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT

LeukemiaLymphocytic8 more

The clinical study of CART19 Cells treatment for MRD of B Cell Malignancies and then auto-HSCT

Unknown status13 enrollment criteria

Pharmacogenomics of Asparaginase Induced Hepatotoxicity

Acute Lymphoblastic Leukemia

This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.

Suspended5 enrollment criteria

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

B-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma

The stunning response rate of anti-CD19(cluster of differentiation antigen 19) auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or refractory B-cell hematologic malignancies. However, based on open clinical trials, using patients' T cells might encounter the failure of apheresis available T cells, even if successful, the time needed for the manufacture could also cause the irreversible disease progress. Furthermore, the cost of auto-CAR-T cells is not affordable for most patients. So to provide an accessible and affordable anti-CD19 CAR-T cell therapy for patients with B-cell hematologic malignancies, we launch such a trial that using the edited T cells from healthy donors to manufacture universal CAR-T cells and adapt it in patients with CD19+ B-cell leukemia or lymphoma.

Unknown status11 enrollment criteria

Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched...

Multiple MyelomaLymphoma3 more

Primary Objective: A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients receiving a non-myeloablative allogeneic SCT from a matched sibling donor, with fludarabine and low-dose TBI, with pre- and post-transplant immunosuppression with tacrolimus and MMF. B. To evaluate the incidence of grade II-IV GVHD associated with this treatment.

Unknown status21 enrollment criteria
1...161162163...182

Need Help? Contact our team!


We'll reach out to this number within 24 hrs